A Clinical Study to Evaluate the Efficacy and Safety of Frevecitinib (KN-002) in Patients With Severe Asthma
NCT07532265
This study is recruiting at 9 US sites in 5 states, according to its ClinicalTrials.gov record last updated .
Summary
A Phase 2 Dose Ranging Study to Evaluate the Efficacy and Safety of Frevecitinib (KN-002) Over a 12-Week Treatment Period in Patients With Severe Asthma Not Controlled With Medium to High Dose ICS/LABA
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Severe Asthma
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 2
- Ages
- 18 to 75 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Kinaset Therapeutics Inc
- Last updated on ClinicalTrials.gov
- July 28, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 2
- Research site · Lancaster, CA
- Research site · San Jose, CA
Florida · 2
- Research site · Miami, FL
- Research site · Tampa, FL
North Carolina · 1
- Research site · Charlotte, NC
South Carolina · 1
- Research site · Rock Hill, SC
Texas · 3
- Research site · Dallas, TX
- Research site · Houston, TX
- Research site · San Antonio, TX
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.